Computed tomography-based radiomics predicts the fibroblast-related gene EZH2 expression level and survival of hepatocellular carcinoma

Table 1 Correlation between key genes and prognosis of hepatocellular carcinoma patients

Characteristic	Total, n	Univariate analysis		Multivariate analysis
		Hazard ratio (95%CI)	P value	Hazard ratio (95%CI)	P value
ATIC	339	1.042 (1.027-1.058)	< 0.001	1.011 (0.989-1.033)	0.348
EZH2	339	1.196 (1.128-1.269)	< 0.001	1.087 (1.006-1.174)	0.035
HDGF	339	1.010 (1.006-1.014)	< 0.001	1.004 (0.999-1.026)	0.104
HEXB	339	1.027 (1.014-1.039)	< 0.001	1.013 (0.999-1.026)	0.060
HSPA4	339	1.040 (1.023-1.058)	< 0.001	1.017 (0.996-1.039)	0.117
NRAS	339	1.066 (1.042-1.091)	< 0.001	1.031 (1.003-1.059)	0.032
PPT1	339	1.030 (1.019-1.041)	< 0.001	1.004 (0.988-1.020)	0.665

CI: Confidence interval.

Table 2 Relationship between risk score and clinicopathological parameters in hepatocellular carcinoma patients

Variables	Total, n = 339	Risk score-low, n = 170	Risk score-high, n = 169	P value
Age	61.000 (51.000, 68.000)	62.000 (52.000, 69.000)	59.000 (51.000, 67.000)	0.083
Sex				0.310
Female	107 (31.6%)	58 (34.1%)	49 (29.0%)
Male	232 (68.4%)	112 (65.9%)	112 (71.0%)
Stage				0.876
S1+S2	252 (74.3%)	127 (74.7%)	125 (74.0%)
S3+S4	87 (25.7%)	43 (25.3%)	44 (26.0%)
Grade				0.457
G1+G2	212 (62.5%)	103 (60.6%)	109 (64.5%)
G3+G4	127 (35.5%)	67 (39.4%)	60 (35.5%)

S1 + S2: Stage I and stage II; S3 + S4: Stage III and stage IV.

Table 3 Correlation between risk scores in clinical features and hepatocellular carcinoma prognosis

Characteristic	Total, n	Multivariate analysis
		Hazard ratio (95%CI)	P value
Risk score	339	5.339 (3.139-9.078)	< 0.001
Age	339	1.018 (1.002-1.034)	0.028
Sex	339	1.010 (1.006-1.014)	0.172
Grade	339	1.113 (0.744-1.664)	0.603
Stage	339	0.888 (0.579-1.363)	0.588

CI: Confidence interval.

Table 4 Binding energy between EZH2 and four chemotherapy drugs in molecular docking

Medicine	Hub targets (PDB ID)	Binding energy in kcal/mol
Belinostat	EZH2 (5h14)	-4.58
BRD-K34222889	EZH2 (5h14)	-4.23
Ciclopirox	EZH2 (5h14)	-4.07
Cytarabine hydrochloride	EZH2 (5h14)	-1.75

PDB ID: Protein database ID.

Table 5 Difference in the area under the curves of EZH2, NRAS, and the risk score in diagnosing hepatocellular carcinoma

Name	EZH2	NRAS	Risk score
EZH2	/	< 0.05	< 0.05
NRAS	< 0.05	/	< 0.05
Risk score	< 0.05	< 0.05	/

/: Not applicable.

Table 6 Results of predicting EZH2 in the training set and validation set based on the logistic and random forest classifier algorithm

Classification model		AUC	Accuracy	Sensitivity	Specificity	F1 score
Validation	Logistic	0.792	0.667	0.800	0.833	0.833
	Random Forest	0.812	0.750	1.000	0.750	0.833
Training	Logistic	0.787	0.750	0.679	0.881	0.744
	Random Forest	1.000	0.938	1.000	1.000	1.000

AUC: Area under the curve.